Active Recombinant Mouse Lgals9
Cat.No. : | Lgals9-695M |
Product Overview : | Recombinant Mouse Lgals9 (Accession # NP_001152773) Ala2-Thr322 was produced in E. coli-derived. |
- Specification
- Gene Information
- Related Products
Source : | E. coli |
Species : | Mouse |
Predicted N Terminal : | Ala2 |
Form : | Lyophilized from a 0.2 µm filtered solution in MOPS, NaCl, EDTA, DTT and Trehalose. |
Bio-activity : | Measured by the ability of the immobilized protein to support the adhesion of D10.G4.1 mouse helper T cells.The ED50 for this effect is typically 0.6-3 µg/mL. |
Molecular Mass : | Recombinant Mouse Lgals9 has a calculated MW of 36.4 kDa. In SDS-PAGE migrates as 36 kDa, reducing conditions. |
Purity : | >95%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
Storage : | Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC). |
Gene Name : | Lgals9 lectin, galactose binding, soluble 9 [ Mus musculus ] |
Official Symbol : | Lgals9 |
Synonyms : | LGALS9; lectin, galactose binding, soluble 9; galectin-9; lectin, galactose binding, soluble 5; gal-9; Lgals5; LGALS35; AA407335; AI194909; AI265545; |
Gene ID : | 16859 |
mRNA Refseq : | NM_001159301 |
Protein Refseq : | NP_001152773 |
MIM : |
Products Types
◆ Recombinant Protein | ||
LGALS9-5058M | Recombinant Mouse LGALS9 Protein, His (Fc)-Avi-tagged | +Inquiry |
LGALS9-660H | Recombinant Human LGALS9 Protein | +Inquiry |
LGALS9-3048R | Recombinant Rat LGALS9 Protein, His (Fc)-Avi-tagged | +Inquiry |
LGALS9-1291H | Recombinant Human LGALS9 Protein, His (Fc)-Avi-tagged | +Inquiry |
LGALS9-195H | Active Recombinant Human LGALS9 Protein (Ala2-Thr355), N-His tagged, Animal-free, Carrier-free | +Inquiry |
◆ Lysates | ||
LGALS9-4761HCL | Recombinant Human LGALS9 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionYes, there are clinical trials investigating the use of LGALS9-based therapies in cancer treatment, with a focus on immunotherapy approaches.
There is emerging research on the potential use of LGALS9 in modulating immune responses to infectious diseases, particularly in the context of viral infections.
Challenges include optimizing the delivery and dosing of LGALS9-based therapies and addressing potential adverse effects on immune homeostasis.
LGALS9 is being investigated for its potential to induce immune tolerance and mitigate transplant rejection in preclinical studies.
LGALS9 has been found to promote the activation and proliferation of cytotoxic T lymphocytes, which are key players in the immune response against cancer cells.
Customer Reviews (3)
Write a reviewIt has demonstrated outstanding performance in ELISA, providing reliable and precise results.
It has been invaluable in protein electron microscopy structure analysis, facilitating detailed investigations and yielding valuable insights.
I highly recommend the LGALS9 protein for various experimental applications.
Ask a Question for All Lgals9 Products
Required fields are marked with *
My Review for All Lgals9 Products
Required fields are marked with *
Inquiry Basket